

Q7 9. (Thrice Amended) A compound according to claim 6, wherein one or more amino acids is replaced by its corresponding D-amino acid.

Q8 11. (Thrice Amended) A compound according to claim 6, wherein the compound is labelled with a detectable marker.

Q9 34. (Once Amended) A compound according to claim 6, wherein the contiguous sequence represents residues 149 to 177 of the G protein of RSV.

35. (Once Amended) A diagnostic composition comprising a compound according to claim 6.

Q10 39. (Once Amended) A composition comprising a compound according to claim 6, together with a pharmaceutically acceptable carrier.

Q11 41. (Once Amended) A composition comprising a compound according to claim 6, wherein one or more amino acids is replaced by its corresponding D-amino acid.

Sub. 917
Q12 Please add new claims 43-50, as follows:

43. (New) A compound comprising the amino acid sequence KQRQNKPPSKPNNDHFHFEVFNFVPCSICG (SEQ ID NO:39), wherein the cysteine residues are derivatized with acetamidomethyl.

44. (New) The compound acetyl-KQRQNKPPSKPNNDFHFEVFNFVPCSICGAmide (SEQ ID NO:39), wherein the cysteine residues are derivatized with acetamidomethyl.

45. (New) A method of inhibiting the cytopathic effect of RSV, comprising contacting an RSV susceptible cell with the compound of claim 6.

Sub. 81
46. (New) A method according to claim 45, wherein the contiguous sequence of amino acids represents residues 149 to 177 of the G protein of RSV.

47. (New) A method according to claim 45, wherein the compound comprises the amino acid sequence KQRQNKPPSKPNNDFHFEVFNFVPCSICG (SEQ ID NO:39), wherein the cysteine residues are derivatized with acetamidomethyl.

48. (New) A method according to claim 45, wherein the compound is acetyl-KQRQNKPPSKPNNDFHFEVFNFVPCSICGAmide (SEQ ID NO:39), wherein the cysteine residues are derivatized with acetamidomethyl.

49. (New) A method of inhibiting the cytopathic effect of RSV, comprising contacting an RSV susceptible cell with a compound comprising a contiguous sequence of amino acids within the sequence representing residues 149-197 of the G protein of respiratory syncytial virus (RSV).

50. (New) A compound comprising a contiguous sequence of amino acids within the sequence representing residues 149-197 of the G protein of respiratory syncytial virus (RSV), wherein none of cysteines 173, 176, 182 and 186 is functional to form a disulfide bridge,

wherein said compound is not glycosylated, and wherein said compound has the ability to inhibit infectivity of RSV.

Q12
Sub. P17